Merck KGaA Sponsored ADR (MKKGY)
OTC PINK OTC PINK Primary Summary
MKKGY Chart
MKKGY or STVN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Is Merck KGaA (MKKGY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merck KGaA Sponsored ADR Dividends
| MKKGY In 9 months Estimated | Annual | $0.5 Per Share |
| MKKGY 2 months ago Paid | Annual | $0.5 Per Share |
| MKKGY 29 Apr 2024 Paid | Annual | $0.47 Per Share |
| MKKGY 2 May 2023 Paid | Annual | $0.47 Per Share |
| MKKGY 25 Apr 2022 Paid | Annual | $0.39 Per Share |
| MKKGY 26 Apr 2021 Paid | Annual | $0.33 Per Share |
Merck KGaA Sponsored ADR Earnings
| 7 Aug 2025 (In 1 week) Date | | 0.49 Cons. EPS | - EPS |
| 15 May 2025 Date | | 0.5 Cons. EPS | 0.47 EPS |
| 6 Mar 2025 Date | | 0.45 Cons. EPS | 0.45 EPS |
| 14 Nov 2024 Date | | 0.49 Cons. EPS | 0.49 EPS |
| 1 Aug 2024 Date | | 0.44 Cons. EPS | 0.47 EPS |
| MKKGY In 9 months Estimated | Annual | $0.5 Per Share |
| MKKGY 2 months ago Paid | Annual | $0.5 Per Share |
| MKKGY 29 Apr 2024 Paid | Annual | $0.47 Per Share |
| MKKGY 2 May 2023 Paid | Annual | $0.47 Per Share |
| MKKGY 25 Apr 2022 Paid | Annual | $0.39 Per Share |
| MKKGY 26 Apr 2021 Paid | Annual | $0.33 Per Share |
| 7 Aug 2025 (In 1 week) Date | | 0.49 Cons. EPS | - EPS |
| 15 May 2025 Date | | 0.5 Cons. EPS | 0.47 EPS |
| 6 Mar 2025 Date | | 0.45 Cons. EPS | 0.45 EPS |
| 14 Nov 2024 Date | | 0.49 Cons. EPS | 0.49 EPS |
| 1 Aug 2024 Date | | 0.44 Cons. EPS | 0.47 EPS |
Merck KGaA Sponsored ADR (MKKGY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Merck KGaA Sponsored ADR ever had a stock split?
Merck KGaA Sponsored ADR Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Ms. Belen Garijo Lopez M.D. CEO | OTC PINK Exchange | US5893392093 ISIN |
| DE Country | 59,020 Employees | 29 Apr 2025 Last Dividend | 15 Aug 2017 Last Split | - IPO Date |
Overview
Merck KGaA is a distinguished science and technology company based in Darmstadt, Germany, with a comprehensive operation span across Life Science, Healthcare, and Electronics segments. It embodies a rich history of innovation and expertise since its foundation in 1668. Merck KGaA is noted not only for its extensive product portfolio and research and development initiatives but also for its significant contributions to various industries, including biotech, pharmaceuticals, and electronics. With a global presence, Merck KGaA continues to be a pivotal force in advancing scientific discovery and technological advancements. This esteemed company operates as a subsidiary of E. Merck KGaA, further reinforcing its strong lineage and commitment to excellence in the science and technology domain.
Products and Services
- Life Science Solutions
Merck KGaA's Life Science segment caters to academic laboratories, biotech, and pharmaceutical manufacturers, as well as the industrial sector. It offers a wide range of tools, chemicals, and equipment essential for scientific research and development. This includes providing drug manufacturers with process development expertise, continuous bioprocessing technologies, testing kits and services, and solutions for analyzing air, water, and soil. Also available are products and tools for testing nutritional value and identifying quality inconsistencies, underscoring the company’s role in bolstering scientific inquiry and production efficiency.
- Healthcare Products
In the Healthcare segment, Merck KGaA focuses on discovering, developing, manufacturing, and marketing prescription drugs and biopharmaceuticals. It addresses a broad spectrum of conditions across oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. The segment is also responsible for producing general medicines, injection devices, and disease monitoring software, showcasing its dedication to enhancing patient care and medical outcomes worldwide.
- Electronics Materials
The Electronics segment of Merck KGaA supplies critical materials to the semiconductor and display industries, enhancing the quality and efficiency of electronic devices. This includes delivery systems and services, as well as innovative surface solutions such as cosmetics, effect pigments, and functional solutions. Through this segment, Merck KGaA drives the evolution of electronic surfaces, contributing to the development of advanced and aesthetically pleasing electronic products.
- Partnering and Collaborations
Merck KGaA has established several in-licensing agreements and collaborations to enhance its product offerings and expand its research capabilities. This includes partnerships with Debiopharm International SA for head and neck cancer treatments, Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drugs, and Abbisko Therapeutics Co. Ltd. for addressing tenosynovial giant cell tumor. Moreover, it has a licensing and collaboration agreement with Merck KGaA for the discovery of two targeted protein degraders, aimed at critical oncogenic proteins, signifying its commitment to combating cancer through innovative therapeutic solutions.
Contact Information
